ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50-Day Moving Average of $2.16

ProQR Therapeutics (NASDAQ:PRQR) shares passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $2.16 and traded as high as $2.20. ProQR Therapeutics shares last traded at $2.05, with a volume of 319,416 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on PRQR shares. StockNews.com lowered ProQR Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of ProQR Therapeutics in a report on Thursday, March 14th. Finally, Chardan Capital raised their price objective on shares of ProQR Therapeutics from $2.00 to $2.50 and gave the company a “buy” rating in a report on Thursday, March 14th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $3.56.

ProQR Therapeutics Price Performance

The company has a fifty day simple moving average of $2.15 and a 200 day simple moving average of $1.87. The stock has a market capitalization of $154.58 million, a price-to-earnings ratio of -5.15 and a beta of 0.21. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.54 and a current ratio of 3.54.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). The company had revenue of $3.54 million for the quarter, compared to analyst estimates of $27.88 million. ProQR Therapeutics had a negative return on equity of 56.71% and a negative net margin of 431.65%. Equities research analysts forecast that ProQR Therapeutics will post -0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On ProQR Therapeutics

A number of hedge funds have recently bought and sold shares of PRQR. Monaco Asset Management SAM grew its holdings in ProQR Therapeutics by 58.9% during the 3rd quarter. Monaco Asset Management SAM now owns 377,517 shares of the biopharmaceutical company’s stock worth $491,000 after acquiring an additional 140,000 shares during the period. Jane Street Group LLC boosted its position in shares of ProQR Therapeutics by 198.0% during the 1st quarter. Jane Street Group LLC now owns 55,868 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 37,121 shares in the last quarter. GSA Capital Partners LLP grew its stake in ProQR Therapeutics by 69.0% during the third quarter. GSA Capital Partners LLP now owns 74,084 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 30,248 shares during the period. Virtu Financial LLC bought a new stake in ProQR Therapeutics in the fourth quarter worth approximately $69,000. Finally, Mariner LLC bought a new stake in ProQR Therapeutics in the fourth quarter worth approximately $68,000. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).